OBJECTIVE: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. METHODS: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. RESULTS: Base case results demonstrate that scenario 1 is associated with a cost per QALY of €30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of €32,752.44 per QALY when scenario 1 is compared with scenario 3. CONCLUSION: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.
OBJECTIVE: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. METHODS: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. RESULTS: Base case results demonstrate that scenario 1 is associated with a cost per QALY of €30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of €32,752.44 per QALY when scenario 1 is compared with scenario 3. CONCLUSION: The use of eltrombopag in HCVpatients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.
Authors: Loreta A Kondili; Federica Romano; Francesca Romana Rolli; Matteo Ruggeri; Stefano Rosato; Maurizia Rossana Brunetto; Anna Linda Zignego; Alessia Ciancio; Alfredo Di Leo; Giovanni Raimondo; Carlo Ferrari; Gloria Taliani; Guglielmo Borgia; Teresa Antonia Santantonio; Pierluigi Blanc; Giovanni Battista Gaeta; Antonio Gasbarrini; Luchino Chessa; Elke Maria Erne; Erica Villa; Donatella Ieluzzi; Francesco Paolo Russo; Pietro Andreone; Maria Vinci; Carmine Coppola; Liliana Chemello; Salvatore Madonia; Gabriella Verucchi; Marcello Persico; Massimo Zuin; Massimo Puoti; Alfredo Alberti; Gerardo Nardone; Marco Massari; Giuseppe Montalto; Giuseppe Foti; Maria Grazia Rumi; Maria Giovanna Quaranta; Americo Cicchetti; Antonio Craxì; Stefano Vella Journal: Hepatology Date: 2017-10-30 Impact factor: 17.425